Dwight H Owen
ECOG-ACRIN Cancer Research Group · Ohio State University Comprehensive Cancer Center · Ohio State University Comprehensive Cancer Center LAO
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Dwight H Owen as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 11:50 UTC. Open this list on ClinicalTrials.gov
- Ph3NCT06732401 · Testing the Addition of AZD6738 (Ceralasertib) to Immunotherapy to Increase Time Without Cancer for Patients With Non-Small Cell Lung CancerNational Cancer Institute (NCI) · active not recruiting · Lung Non-Small Cell Carcinoma, Stage II Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8 · principal investigator
- Ph1NCT06616623 · Vismodegib and Atezolizumab for the Treatment of Recurrent or Metastatic Non-Small Cell Lung CancerDwight Owen · suspended · Metastatic Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8 · principal investigator
- Ph1NCT05234307 · PBF-1129 and Nivolumab for the Treatment of Recurrent or Metastatic Non-Small Cell Lung CancerDwight Owen · recruiting · Metastatic Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8 · principal investigator
- Ph1NCT04919369 · All-Trans Retinoic Acid (ATRA) and Atezolizumab for the Treatment of Recurrent or Metastatic Non-Small Cell Lung CancerDwight Owen · completed · Metastatic Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8 · principal investigator
- Ph1/Ph2NCT03831932 · Telaglenastat Hydrochloride and Osimertinib in Treating Patients With EGFR-Mutated Stage IV Non-small Cell Lung CancerNational Cancer Institute (NCI) · active not recruiting · Advanced Lung Non-Small Cell Carcinoma, Metastatic Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8 · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 11:50 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
- Clinical Trial Concept in the Oncology LandscapeR25CA278725 · NCI · OHIO STATE UNIVERSITY · fiscal years 2024 to 2026 · $264,604 awarded in 2026Same name and institution; not confirmed by an ID
- OSU as a Network Lead Academic Participating Site for the NCI NCTNUG1CA233331 · NCI · OHIO STATE UNIVERSITY · fiscal years 2026 · $1,100,102 awarded in 2026Same name and institution; not confirmed by an ID
- Targeting Tumor-Associated Macrophages via Hedgehog Inhibition to Enhance Immunotherapy in Non-Small Cell Lung CancerR21CA299786 · NCI · OHIO STATE UNIVERSITY · fiscal years 2025 to 2026 · $184,492 awarded in 2026Same name and institution; not confirmed by an ID
- Cachexia-mediated FcRn Modulation and Its Impact on Anti-PD1 Therapy in Lung CancerR01CA273924 · NCI · OHIO STATE UNIVERSITY · fiscal years 2022 to 2025 · $1,263,739 awarded in 2025Same name and institution; not confirmed by an ID
NIH grants that fund their trials
These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.
- ECOG-ACRIN Network Group Operations CenterU10CA180820 · NCI · ECOG-ACRIN MEDICAL RESEARCH FOUNDATION · PI Peter J ODwyer, MITCHELL D. SCHNALL · fiscal years 2014 to 2026Named on NCT06732401
- Targeting immunosuppressive adenosine in patients with metastatic non-small cell lung cancerR01CA248741 · NCI · OHIO STATE UNIVERSITY · PI DAVID P. CARBONE · fiscal years 2021 to 2025Named on NCT05234307
- The Ohio State University as a Lead Academic Organization (LAO) for the Experimental Therapeutics Clinical Trials NetworkUM1CA186712 · NCI · OHIO STATE UNIVERSITY · PI SUSANNE M ARNOLD, WILLIAM E. CARSON, Narendranath Epperla · fiscal years 2014 to 2026Named on NCT03831932
Most cited trial papers
Clinical-trial papers with this author name in non-small cell lung cancer, ranked by citations from NIH iCite, fetched 2026-11-12 11:50 UTC. The ranking covers the 200 most relevant of 4 PubMed records, and a shared surname and initials can bring in a namesake. All 4 on PubMed
- Neoadjuvant atezolizumab for resectable non-small cell lung cancer: an open-label, single-arm phase II trial.Nat Med · 2022245 citationsRCR 14.0
- Intracranial Efficacy of Selpercatinib in RET Fusion-Positive Non-Small Cell Lung Cancers on the LIBRETTO-001 Trial.Clin Cancer Res · 2021127 citationsRCR 6.6
- Surgical results of the Lung Cancer Mutation Consortium 3 trial: A phase II multicenter single-arm study to investigate the efficacy and safety of atezolizumab as neoadjuvant therapy in patients with stages IB-select IIIB resectable non-small cell lung cancer.J Thorac Cardiovasc Surg · 202335 citationsRCR 2.0
- Phase 1 dose escalation trial of the selective adenosine A2B antagonist PBF-1129 in patients with metastatic non-small cell lung cancer.Invest New Drugs · 20254 citationsRCR 1.0